aspirin has been researched along with cox 189 in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blobaum, AL; Marnett, LJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P | 1 |
| Branson, J; Guillaume, M; Jermany, J; Rordorf, C; Schmouder, R | 1 |
| Bishop-Bailey, D; Mitchell, JA; Vojnovic, I; Warner, TD | 1 |
| Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW | 1 |
| Hawkey, CJ; Krammer, G; Murphy, V; Rebuli, R; Richard, D; Stricker, K; Weinstein, WM | 1 |
| Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
3 review(s) available for aspirin and cox 189
| Article | Year |
|---|---|
Structural and functional basis of cyclooxygenase inhibition.
Topics: Animals; Cardiovascular System; Crystallography, X-Ray; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; History, 18th Century; History, 19th Century; History, 20th Century; History, 21st Century; History, Ancient; Humans; Kinetics; Models, Molecular; Protein Conformation; Risk Assessment | 2007 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
4 trial(s) available for aspirin and cox 189
| Article | Year |
|---|---|
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Health Status; Humans; Ibuprofen; Isoenzymes; Membrane Proteins; Middle Aged; Naproxen; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Prognosis; Prostaglandin-Endoperoxide Synthases; Risk Factors | 2004 |
Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.
Topics: Adolescent; Adult; Arachidonic Acid; Aspirin; Collagen; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Epoprostenol; Female; Humans; Male; Middle Aged; Organic Chemicals; Platelet Aggregation; Platelet Aggregation Inhibitors; Thromboxane B2 | 2005 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis | 2007 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Statistics as Topic | 2008 |
3 other study(ies) available for aspirin and cox 189
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2.
Topics: Aspirin; Blood Platelets; Blood Proteins; Calcimycin; Calcium; Celecoxib; Cell Line; Cerebrospinal Fluid Proteins; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Humans; Indomethacin; Ionophores; Lactones; Meloxicam; Naproxen; Organ Specificity; Organic Chemicals; Protein Binding; Pyrazoles; Sodium Salicylate; Sulfonamides; Sulfones; Synovial Fluid; Thiazines; Thiazoles; Thromboxane A2 | 2006 |